Already Registered? Log In Now
Not Registered?
Business Email:
Complete this form to enter the webcast.
Already Registered?
(* indicates required field)
Complete this form to enter the webcast.
(* indicates required field)
Business Email*:
First Name*:
Last Name*:
Title*:
Company Name*:
Street Address 1*:
Street Address 2:
City*:
State/Province*:
--
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
Postal Code*:
Country*:
--
Afghanistan
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, The Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libyan Arab Jamahiriya
Liechtenstein
Lithuania
Luxembourg
Macao
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Macedonia, Republic of
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French Part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch Part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan
Tajikistan
Tanzania, United Republic of
Thailand
Timor-leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States Minor Outlying Islands
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
Business Phone:
Which best describes your job function?:
--
Clinical Research
Commercial Operations
Commercialization
Compliance
Consultant
Contract Services
Corporate Management
Drug Safety
Engineering
Environmental
Finance
HR
IT
Lab Management
Legal
Managed Care
Manufacturing/Processing
Market Research
Marketing
Media Planning
Medical Affairs
Medicare/Medicaid
Meeting Planner
Other
Packaging
Patient Programs/Services
Pharmacy
Procurement
Project Management
QA/QC
R&D
Regulatory Affairs
Reimbursement
Sales Management
Scientific
Supply Chain
Technology Transfer
Trade/Sales
Validation
X-Outcomes
Which best describes your business/industry?:
--
Academic
Audit & Financial Advisory
Biopharma
Bio Pharmaceutical
Biotech
Consultant
Contract Manufacturing Organization (CMO)
Contract Research Organization (CRO)
Convention/Visitors Bureau
Data Management/Technology Provider
Diagnostics
DMC (Destination Management Company)
Food
Government
Health Plan/Payer
Hospital/Medical Centers
Hotel
Laboratory
Legal/Law Firm
Marketing/Creative Agency
Medical Device
Non Profit
PBM (Pharmacy Benefit Management)
Pharmaceutical
Retail Pharmacy
Solutions Provider
Third Party Meeting Manager
Wholesaler/Distributer
checked
Yes, please subscribe me to BioPharm International's free e-newsletters.
By registering for this event, you agree to MJH Life Sciences ®
Terms and Conditions
,
Privacy Policy
, and understand your data will be used by MJH and its affiliates for amongst other things, alerting you to other services or products that you maybe interested in, and may be shared with or sold to third parties for their use, including possible contact with you through email or other communications, consistent with their respective privacy policy. If you do not agree to have your data used in this way, please contact
info@mjhassoc.com
.
*Denotes required.
A Novel Conjugation Technology that Generates ADCs with a Narrowly Distributed DAR
Wed, Dec 13, 2023 11:00 AM EST{LOCAL_TZ}
Event Overview:
Conventional conjugation methods result in heterogeneous ADC products due to a wide drug-to-antibody ratio (DAR) distribution. Over the last decade, many site-specific conjugation technologies have been developed to address this issue, yet the improved homogeneity usually comes with a cost and other technical challenges. To address these concerns, WuXi XDC developed the novel WuXiDARx™ technology platform, featuring a myriad of benefits for ADC development and manufacturing. This webinar will outline those key elements that result in ADCs generated with ideal developability characteristics and strong
in vitro
and
in vivo
profiles when compared to reference ADCs generated using other conjugation approaches. The enhanced preclinical advantages of the WuXiDARx ADCs may lead to better clinical efficacy and safety and thus far, six ADC molecules generated using one of the WuXiDARx platforms (WuXiDAR4™) have finished large-scale GMP runs and entered phase I clinical trials. Multiple case studies and data comparing the ADC quality attribute profiles of WuXiDARx-generated ADCs will be presented.
Key Learning Objectives:
Understand current challenges in the discovery and development of Antibody Drug Conjugates (ADCs) including the ability to establish ADC molecules with a narrowly distributed drug-to-antibody ratio (DAR)
Difficulties and challenges associated with current methodologies for establishing ADCs with consistent and homogeneous DAR
Introduction of the WuXiDARx technology platform that reliably generates homogeneous DAR for the most clinically validated DAR formats (DAR2, DAR4, DAR6)
Who Should Attend:
Chemists/biochemists and bioconjugation scientists, managers, directors, and vice presidents of R&D, drug discovery, ADC discovery, ADC development, ADC manufacturing, ADC CMC development, supply chain, technology assessment, technology in-licensing. Also, chief technical officers and chief scientific officers of companies developing antibody drug conjugates.
That is,
Anyone / any company developing antibody drug conjugates (ADCs) for clinical trials
Teams struggling with establishing homogenous or a narrow distribution of drug antibody ratio (DAR) in their ADC discovery, development or manufacturing programs
Teams that need a more flexible DAR methodology for their various ADC programs that is compatible with multiple DAR formats (e.g., DAR2, DAR4, DAR6 etc.)
Teams looking for more robust, reproducible and cost-effective chemistry/methodology to establish the target DAR for their ADC programs
Featured Speaker:
Qirui Fan, Ph.D.
Associate Director, New Technology Development & Business Support
WuXi XDC, A WuXi Biologics Subsidiary
Dr. Qirui Fan
is an associate director of new technology development at WuXi XDC. He obtained his bachelor’s degree in pharmaceutical engineering in 2010 and doctorate degree in chemical engineering from The Ohio State University in 2015. He specialized in nanoparticle-Ab conjugates R&D at Core Quantum Technologies in 2015-2020, and led the development of two product lines: 1) “MultiDots” (fluorescent nanoparticles) for multi-channel flow cytometry characterization; and 2) “MagDots” (fluorescent-magnetic nanoparticles) for cell separation. He joined the Bioconjugation Department of WuXi Biologics/WuXi XDC in 2021. His primary responsibility includes new conjugation technology service, novel technology evaluations and ADC discovery client service. Recently, his team updated the WuXiDAR4 technology, and expanded it to include target DAR of 2 and 6.
Speaker’s Email:
fan_qirui@wuxibiologics.com
For any technical questions please contact David Ambrose:
dambrose@mjhlifesciences.com
FAQs and System Test
Outlook ❯
Google ❯